StockNews.com Initiates Coverage on Evogene (NASDAQ:EVGN)

Equities researchers at StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Trading Up 0.2 %

EVGN stock opened at $4.16 on Wednesday. The stock has a market cap of $171.46 million, a PE ratio of -9.04 and a beta of 1.40. Evogene has a 12 month low of $3.79 and a 12 month high of $10.40. The company has a 50-day moving average price of $5.73 and a 200 day moving average price of $6.97.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Thursday, May 23rd. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter. The firm had revenue of $4.19 million during the quarter. Evogene had a negative return on equity of 70.96% and a negative net margin of 233.66%.

Institutional Trading of Evogene

An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets increased its stake in Evogene Ltd. (NASDAQ:EVGN) by 30.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 91,400 shares of the biotechnology company’s stock after buying an additional 21,500 shares during the period. BNP Paribas Financial Markets owned 0.22% of Evogene worth $69,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.